A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
The Impact of the Establishment of a New AMS CPS in a Rural Hospital in Austria
- Status
- UNKNOWN
- Phase
- N/A
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab Plus Olaparib in LA-HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
- Status
- COMPLETED
- Phase
- N/A
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
- Status
- TERMINATED
- Phase
- PHASE2
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
- Status
- COMPLETED
- Phase
- PHASE1
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
- Status
- RECRUITING
- Phase
- N/A
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
- Status
- COMPLETED
- Phase
- N/A
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2